GE buys U.S. healthcare consultancy; Eisai licenses cancer surgery visualization tech;

@FierceMedDev: ICYMI yesterday: Google Life Sciences teams with AHA to target heart disease in $50M research initiative. Article | Follow @FierceMedDev

@VarunSaxena2: JAMA study: Rate of inappropriate stenting is declining. Story | Follow @VarunSaxena2

@EmilyWFierce: Scientists make strides toward full-body PET scanner with $15.5M in tow. Article | Follow @EmilyWFierce

> GE Healthcare ($GE) has acquired U.S. healthcare consultancy The Camden Group for an undisclosed sum. It will become the U.S. arm of its global advisory firm GE Healthcare Partners. More

> The Wall Street Journal is featuring a couple of med tech stories--one on medical apps and the other on hacking the brain with devices.

> Eisai's Morphotek has licensed Tumor Paint technology from Seattle, WA-based startup Blaze Bioscience to develop a means to visualize cancer cells during surgery via a tumor-targeting chlorotoxin derivative linked to a near-infrared diagnostic agent. More

Biotech News

@FierceBiotech: ICYMI yesterday: Agios slips on mixed solid tumor data for its Celgene-partnered cancer drug. More | Follow @FierceBiotech

@JohnCFierce: Old ACT was always reliable. Every fresh bit of data was a revolutionary breakthrough. But never got out of early stage R&D. | Follow @JohnCFierce

@DamianFierce: "I can't believe the future is sending feces around the country," said $MCBM's CEO, having never heard of Twitter. More from the NYT | Follow @DamianFierce

> AstraZeneca, GlaxoSmithKline stake rival claims on new lupus therapies. Story

> MiRagen captures a $41M round for a pair of microRNA trials. Article

> Did Sanofi drag its feet on Lemtrada to shortchange Genzyme shareholders? More

Pharma News

@FiercePharma: Luye's schizophrenia drug gets nod to move ahead with NDA approval. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: $VRX "working hard" to reach out to payers, CEO says. "Historically, I have not spent a lot of time doing that." | Follow @CarlyHFierce

> Short-seller Citron spotlights Mallinckrodt as 'worse offender' than Valeant. Report

> J&J slapped with $1.8M verdict in Risperdal breast growth case. Article

Drug Delivery News

> Injectable HIV regimen being developed by J&J and ViiV Healthcare shows promise in trials. Report

> Canadian doctor opens blood-brain barrier using focused ultrasound. Item

> Ebola study will monitor viral entry into cells, with focus on drug delivery. Story

> Injectable HIV regimen being developed by J&J and ViiV Healthcare shows promise in trials. Article

> GSK beats AstraZeneca to finish line, wins FDA approval of first anti-IL-5 injectable for asthma. More

Pharma Manufacturing News

> Court orders Dr. Reddy's to temporarily halt sales of its purple Nexium copy. Story

> Pfizer recalls 21,000 bottles of Xanax that may be too weak. More

> Almac expanding in U.K., investing $24M in Charnwood tech park. Report

> Dr. Reddy's gets slapped with FDA warning letter for three Indian plants. Article

> Sun's U.S. sales crater as plant issues cut deeply. Story

Pharma Asia News

> AstraZeneca shows more solid gains in China on respiratory. More

> Luye's schizophrenia drug gets nod to move ahead with NDA approval. Story

> China to restart mainland IPOs, with pharma ready to roll. Item

> FDA widens review of Dr. Reddy's manufacturing ops. More

> India's Sun Pharmaceutical takes another Ranbaxy-related hit. Article

Suggested Articles

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.

In one of the longest studies to date in high-risk heart disease, researchers found no significant difference in death rates over more than 10 years.